Andrew Weinberg
President & Chief Scientific Officer AgonOx
Seminars
Wednesday 18th November 2026
Expanding TIL Clinical Activity Beyond Melanoma by Selectively Enriching Tumor Reactive T-cells
11:30 am
- Demonstrating clinical feasibility of isolating tumor reactive T-cells across multiple solid tumor types
- Sharing early phase safety and response observations from a selective TIL approach
- Informing future trial design by linking cell composition to clinical outcomes
Wednesday 18th November 2026
Panel Discussion: Reducing Development Risk by Evaluating Genetic Editing Strategies Shaping the Future of TIL Therapies
2:10 pm
- Comparing genome editing approaches used to enhance potency, persistence, and tumor recognition
- Reviewing safety, manufacturability, and regulatory trade-offs of engineered TIL designs
- Identifying where genetic modification adds clear clinical value vs. added complexity
- Can TIL manufacturing be designed for in vivo development rather than culturing the cells in vitro?
